Log in

NASDAQ:MYGN - Myriad Genetics Stock Price, Forecast & News

$19.42
-0.12 (-0.61 %)
(As of 02/17/2020 06:00 AM ET)
Add
Today's Range
$19.38
Now: $19.42
$20.09
50-Day Range
$19.42
MA: $26.85
$29.53
52-Week Range
$19.08
Now: $19.42
$48.40
Volume853,911 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:MYGN
CUSIP62855J10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees2,600
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.


Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its earnings results on Thursday, February, 6th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.01. The firm earned $195.10 million during the quarter, compared to analyst estimates of $209.61 million. The business's revenue for the quarter was down 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.38 earnings per share. View Myriad Genetics' Earnings History.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Myriad Genetics.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of approx $0.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.02. The company issued revenue guidance of approx $735 million, compared to the consensus revenue estimate of $807.66 million.

What price target have analysts set for MYGN?

8 Wall Street analysts have issued 12-month price objectives for Myriad Genetics' shares. Their forecasts range from $17.00 to $36.00. On average, they expect Myriad Genetics' share price to reach $25.63 in the next year. This suggests a possible upside of 32.0% from the stock's current price. View Analyst Price Targets for Myriad Genetics.

What is the consensus analysts' recommendation for Myriad Genetics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 4 hold ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.

Has Myriad Genetics been receiving favorable news coverage?

News articles about MYGN stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myriad Genetics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Myriad Genetics.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a decrease in short interest in January. As of January 31st, there was short interest totalling 12,820,000 shares, a decrease of 6.2% from the January 15th total of 13,670,000 shares. Based on an average daily volume of 1,025,600 shares, the days-to-cover ratio is presently 12.5 days. Currently, 17.8% of the company's shares are short sold. View Myriad Genetics' Current Options Chain.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:
  • Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
  • Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (12.05%), State Street Corp (5.22%), Earnest Partners LLC (4.84%), Bank of New York Mellon Corp (1.25%), New York State Common Retirement Fund (1.23%) and Rothschild & Co. Asset Management US Inc. (1.19%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Baillie Gifford & Co., Royce & Associates LP, Point72 Asset Management L.P., Russell Investments Group Ltd., AQR Capital Management LLC, Bank of New York Mellon Corp and Pictet Asset Management Ltd.. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Nicole Lambert, Ralph L Mcdade and Richard Bryan Riggsbee. View Insider Buying and Selling for Myriad Genetics.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Global Alpha Capital Management Ltd., Earnest Partners LLC, FMR LLC, Renaissance Technologies LLC, Great West Life Assurance Co. Can, Credit Suisse AG and Stifel Financial Corp. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $19.42.


MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  440 (Vote Outperform)
Underperform Votes:  717 (Vote Underperform)
Total Votes:  1,157
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel